Hong Kong company Aesthetic Essentials Limited sells not-FDA-approved, mislabeled injectable botulinum toxin drugs online to U.S. consumers.
What happened
FDA found the violations by reviewing the company's website at www.aesthetic-essentials.com. FDA said the site offered injectable botulinum toxin drugs for sale to U.S. consumers, including a product marketed as "Rentox 200U" with claims for blepharospasm, hyperhidrosis, and cervical dystonia. FDA called these not-FDA-approved new drugs and misbranded drugs (labeling lacks adequate directions for use).
What FDA found
The website offers "Rentox 200U," a botulinum toxin type A drug, for sale to U.S. consumers without an FDA-approved drug application.
FD&C Act § 505(a) [21 U.S.C. § 355(a)]By offering this product online, the company causes an unapproved drug to be introduced into interstate commerce.
FD&C Act § 301(d) [21 U.S.C. § 331(d)]The labeling for the prescription botulinum toxin product does not give adequate directions for a layperson to use it safely, so the drug is misbranded.
FD&C Act § 502(f)(1) [21 U.S.C. § 352(f)(1)]The product is not exempt from the adequate-directions requirement because it is not FDA-approved.
21 CFR 201.115(a)By offering the misbranded drug for sale to U.S. consumers, the company causes it to be introduced into interstate commerce.
FD&C Act § 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA requests that www.aesthetic-essentials.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. It asks for a written response within 15 working days describing steps taken to address violations and prevent recurrence.
Who should pay attention
- online sellers of injectable cosmetic drugs
- clinics and consumers buying imported botulinum toxin
- distributors and brands sourcing aesthetic injectables
This is a summary. Read the original letter on fda.gov.